Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Blood copeptin will be measured during the routine treatment of neonates, children and adolescents on the Intensive Care Unit of the University Children's Hospital Zurich at different time points (admission, 12, 24, 48, 96, 168 hours after admission). These values will be primarily analysed for their variability and their association with arterial hypotension. Blood samples will be drawn together with otherwise medically indicated blood withdrawals to avoid extra harm. Further, copeptin values will be compared to clinical and vital parameters, all of them open-label available during clinical routine. Copeptin's predictive value for patients' outcome will be analysed as secondary outcome.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Copeptin in plasma | Diagnostic Test | Copeptin will be measured in EDTA-Plasma. Samples will be stored for batch analyses later. |
| Measure | Description | Time Frame |
|---|---|---|
| Blood copeptin in arterial normo- and hypotension | Average change of blood copeptin in patients with both arterial normo- and hypotension and different pathologies. | Up to 168 hours. |
| Measure | Description | Time Frame |
|---|---|---|
| Length of stay on the intensive care unit | Association of copeptin values with length of stay on the intensive care unit. | Up to 168 hours. |
| Length of respiratory support | Association of copeptin values with length of respiratory Support. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
This is a study designed to explore Copeptin values in all kinds of critically ill paediatric patients. Patients with normal blood pressures will allow calculating Copeptin reference values for the ones requiring cardiovascular support. Therefore, all patients, irrespective of their medical condition (e.g. medical or surgical, mildly or severely affected) and their age (neonates to adolescents) admitted to the Intensive Care Unit of the University's Children Hospital Zurich will be eligible, as long as they fulfil the mentioned inclusion criteria.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Vinzenco Cannizzaro, MD, PhD | University Children's Hospital, Zurich | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Children's Hospital Zurich | Zurich | 8032 | Switzerland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Aug 17, 2017 | Oct 3, 2017 | Prot_000.pdf |
Not provided
Not provided
Not provided
Not provided
| Up to 168 hours. |
| Length and dose of catecholamine therapy | Association of copeptin values with length and dose of catecholamine therapy. | Up to 168 hours. |
| Rate of death | Rate of death at 28 days. | Up to 168 hours. |